Phase 2 study to improve tolerance of chemotherapy involving cetuximab and multidrug FOLFIRI [folinic acid + fluorouracil + irinotecan], with pharmacokinetic and pharmacogenetic studies, in patients with metastatic colorectal cancer
Latest Information Update: 18 Jul 2023
At a glance
- Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Colorectal cancer
- Focus Adverse reactions; Pharmacogenomic; Proof of concept
- 13 Jul 2023 Results assessing the relationship between cetuximab concentrations, target kinetics and progression-free survival published in the Clinical Pharmacokinetics
- 12 May 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
- 12 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.